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A  key step in complement activation on targets is the deposition of C4b and/ 
or C3b fragments.  These major cleavage products of C3 and C4 can associate 
covalently with the target surface (reviewed in  1) and then serve as anchors for 
the assembly of C3 and C5 convertases, the amplifying enzymes of the cascade. 
This amplification must be focused only on the target and must not occur on 
host cells. Moreover, in the course of this focused amplification,  large numbers 
of nascent C4b and C3b fragments are liberated into the fluid phase. Most react 
with water, but some by chance could bind to nearby host cells and lead to their 
damage.  For this and possibly other reasons, the activities of bound, as well as 
free, C3b and  C4b fragments are under  strict control by a  complex system of 
serum and membrane proteins. 
Recent evidence (2,  3) suggests that  regulation  of the activities of substrate- 
bound C4b and C3b is distinct from control of the fluid phase fragments.  The 
functions of the former are controlled mainly by two membrane  proteins:  the 
C3b/C4b receptor (CR1) 1 and the decay-accelerating factor (DAF). CR1  disso- 
ciates C2 and factor B from C4b and C3b in C3 and C5 convertase complexes 
(2-5) and promotes the cleavage of C3b (2, 4, 6, 7) and C4b (3, 5) by the serum 
enzyme C3b/C4b inactivator (I).  DAF has been shown also to enhance the decay 
dissociation of C2 and factor B from C3 convertases (8, 9). The reason for the 
apparent  redundancy in regulatory activities of the two membrane  factors and 
their respective roles in convertase control has remained unclear. Abnormalities 
of CR1  have  been  found  in  systemic  lupus  erythematosus  (SLE)  (10-13),  a 
condition associated with defective immune complex handling, and abnormalities 
of DAF have been found in paroxysmal nocturnal hemoglobinuria (PNH) (9, 14, 
15), a condition associated with heightened susceptibility of blood, cells to lysis. 
In  the  present paper  we purified  DAF to  homogeneity from  the  stroma  of 
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human  red cells and  studied  its functional properties.  We found that purified 
DAF could be readily taken up into the membrane of red cells and that, once 
incorporated, its main function was not to accelerate the decay of the convertases 
but to prevent their assembly.  Moreover, it appears  that membrane-associated 
DAF,  in  contrast  to  CR1,  can  act  only  within  the  cell  membrane,  and  not 
extrinsically on complement enzymes assembled on targets. 
Materials and Methods 
Buffers,  Reagents,  and Proteins.  Isotonic veronal-buffered saline  (DGVB++),  used  in 
most studies, consisted of 2.5 mM veronal, pH 7.4, 73 mM NaCI,  2.5% dextrose, 0.15 
mM CaCI~, 0.5  mM  MgC12, and 0.1%  gelatin. Isoionic veronal buffer (GVB  ÷÷) lacked 
dextrose but contained 146 mM NaCI. The metal-chelating veronal buffer (GVB-EDTA) 
used in hemolytic assays was prepared without CaCI~ and MgCI~ and was supplemented 
with 10 mM EDTA. Phosphate-buffered saline (PBS) contained 0.02 M sodium phosphate, 
pH 7.4 and 146 mM NaCI. 
C2 (16), C4 (17), C3 (17), C5 (17), factors B (18) and D (19), properdin (P) (20),/31H 
globulin (H) (17) and C3b/C4b inactivator (I) (21) were prepared by previously published 
techniques. I was also obtained commercially (Cordis Laboratories, Miami, FL). C2 was 
oxidized (22) (°~YC2) for some studies.  C1  (23), C6-9  (24), and C3-9 (C-EDTA) were 
prepared from guinea pig serum. The functional activity and purity of each component 
were assessed  by specific hemolytic assays  and,  where appropriate, by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Glycophorin A was a gift of Dr. 
Olga Blumenthal, Albert Einstein College of Medicine. 
Monoclonal anti-CR 1 antibodies were obtained as previously described (11). Polyclonal 
anti-glycophorin antibodies were raised by a single subcutaneous injection of 100 #g of 
glycophorin  A  emulsified  in  complete  Freund's  adjuvant.  Monoclonal  antibodies  to 
glycophorin A were a gift of Dr. Margaret Nichols, New York Blood Center. Polyclonal 
anti-DAF antibodies were raised by subcutaneous injection of rabbits or mice with 5 or 1 
#g,  respectively, of DAF emulsified in  complete Freund's adjuvant.  Rabbits  were not 
further immunized. Mice were boosted intravenously at 6 wk with the same antigen dose. 
When these antibodies were used for developing Western blots of crude DAF preparations 
contaminated with glycophorin or blots of extracts of red cell ghosts, only the DAF band 
was revealed. 
Radiolabeling.  Proteins were labeled with ~esI by the Iodogen method (Pierce Chemical 
Co., Rockford, IL) according to the instructions of the manufacturer. Before the labeling 
of DAF, the protein was concentrated by chromatography on DEAE-Sephacel and the 
Nonidet P-40 (NP-40) concentration reduced to 0.001%. After labeling, unbound  ~25I 
was removed by gel filtration through Sephadex G-25 QS-2A Quick-Sep columns (Isolab 
Inc., Akron, OH), followed by extensive dialysis. 
Cellular  Intermediates.  Sheep erythrocytes (E) were sensitized with rabbit anti-sheep 
hemolysin (A) (Gibco Laboratories, Grand Island, NY).  The resulting EA were washed, 
adjusted to 1 ×  10S/ml in DGVB  ÷+, and, after incubation for 15 min at 30°C with 300 
site-forming units (SFU) of C 1, the intermediates (EAC 1) were pelleted and resuspended 
to 1 ×  108/ml. The EAC1 were then incubated for 20 min at 30°C with 100 SFU of C4 
and  the  cells  (EAC14)  again  pelleted  and  washed.  ~1  SFU  of C4  was  used  for the 
preparation of EAC 141ira and ~ 10 SFU of C4 for the preparation of all intermediates 
bearing C3b. In the latter case, the EAC14 were incubated for 5 min at 30°C with 100 
SFU  of C2  and,  after  pelleting and  resuspension,  the  intermediates  (EAC142)  were 
incubated for 15 min at 30°C with C3. After washing, C2 on the cells (EAC1423) was 
decayed at  30°C.  The  resulting  intermediate  EAC143  was  used  for titration  of the 
classical  pathway C5 convertase or for the preparation of cells bearing the alternative 
pathway C3 convertase (EAC143B or EAC143BP).  For the preparation of EAC143~m, 
EAC 142 cells were treated with ~ 1 SFU of C3. 
Assays.  C4b hemolytic sites were quantitated by sequential incubation of EAC 14 with 
300 SFU  of C2 (or °xYC2) for 5 min at 30°C and C-EDTA for 1 h  at 37°C.  Classical 1560  PREVENTION  OF  COMPLEMENT  ACTIVATION  ON  CELLS  BY  DAF 
pathway C3b hemolytic sites were determined by incubation of EAC 1423 (or EAC 14°xY23) 
with 300 SFU of C5 for 5 min at 30°C and C6-9 for 1 h at 37°C. Alternative pathway 
C3b hemolytic sites were measured by incubation of EAC143 (in DGVB  ÷+) with 20 #g/ 
ml of factor B and excess factor D (in the absence or presence of 12 #g/ml of P) for 30 
min at 30 °C and further incubation of the washed cells with C-EDTA for 1 h at 37 ° C. 
The inhibition of C4b2a functional activity by isolated DAF or DAF-containing prep- 
arations was quantitated as originally described by Nicholson-Weller et al. (8).  Briefly, 
EAC14 were incubated for 5 min at 30°C with C2 at a concentration predetermined to 
yield EAC 142 cells bearing ~ 1.5 C4b2a sites, after spontaneous decay of the washed cells 
in DGVB  +÷ for 15 min at 30°C and incubation with C-EDTA for 1 h at 37°C. EAC142 
were then incubated for 15 min at 30°C in the presence of DAF-containing samples and 
the residual C4b2a sites were developed with C-EDTA. 
C2 (or °xYC2) and factor B titrations were performed by standard methods (25),  The 
kinetics of C3 convertase decay was determined by removal at different times of 200-#1 
aliquots of the cell intermediates (5 x  107/mi in GVB  ÷÷) from a tube placed at 30°C and 
subsequent incubation of the aliquots with 1.3 ml C-EDTA for 1 h at 37°C. Additional 
details of the assays are given in the legends to the figures. 
SDS-PAGE, Radioautography, and Western Blotting.  SDS-PAGE was performed as de- 
scribed by Laemmli (26). Stacking gels of 3% and running gels of 7.5% were used. Samples 
were reduced by the addition of 20%  2-mercaptoethanol. Apparent molecular weights 
were estimated by comparison with standards (Bethesda Research Laboratories, Rockville, 
MD). After the run, gels were fixed by methanol/acetic acid and analyzed by Coomassie 
Blue or silver staining. Radioautographs were exposed at -70°C using X-OMAT XAR- 
5 film. Western blotting was done on nitrocellulose paper by standard methods. 
Purification and Characterization of DAF.  DAF was purified to homogeneity from a 
butanol extract of pooled human erythrocytes (E  hu) stroma.  The modified fractionation 
sequence described by Nicholson-Weller et al. (15) was used in the initial phases of the 
isolation.  Contaminating  CR1  and  glycophorin  A  were  removed  by  treatment  with 
Sepharose  beads  coupled  to  monoclonal antibodies.  The  resulting  fraction was  then 
subjected to additional chromatography on DEAE-Sephacel, followed by molecular sieving 
on high pressure liquid chromatography (HPLC), the details of which will be described 
elsewhere. The DAF preparation was analyzed by SDS-PAGE and silver staining, Western 
blotting, and by radiolabeling followed by HPLC. Upon silver staining, a  single sharp 
band of 70,000 mol wt was observed when 30 ~1 of 28 t~g/ml of protein were loaded in 
the gel (see inset of Fig. 1). By Western blotting, no glycophorin was detectable and, after 
HPLC  purification  of labeled  DAF,  a  single  70,000  mol  wt  band  was  observed on 
radioautographs of SDS-PAGE gels. 
Results 
DAF Incorporates  into  Cell Membranes.  Previous studies (8) have shown that 
purified  DAF accelerates decay dissociation of C4b2a complexes preformed on 
red cell hemolytic intermediates.  These findings have been interpreted to indi- 
cate that DAF functions similarly to C4-binding protein (C4bp), a serum protein 
that inhibits the classical pathway C3 convertase by competitively displacing C2a 
from C4b (27). 
Initial experiments were designed to directly examine the mechanism of the 
DAF-mediated reaction. EAC 14 were divided into aliquots that were incubated 
at 30 °C for 15 min with increasing concentrations of DAF or with DGVB  ++ as 
control, and the cells thoroughly washed by centrifugation. The cells were then 
incubated with a predetermined limited amount of C2 (as described in the legend 
to Fig.  1),  washed,  decayed at  30°C  for  15  min,  and  the residual  C4b2a sites 
developed. The C4b2a hemolytic activity on the DAF-treated and washed cells 
was  markedly  reduced  relative  to  the  buffer-treated  control  cells  (Fig.  1 A). MEDOF,  KINOSH|TA,  AND  NUSSENZWEIG  1561 
FIGURE 1.  (A) Measurement of DAF inhibitory activity on C3 convertase by two independent 
assays, either after its incorporation into EAC 14 intermediates (A), or directly on preformed 
EAC142 (O).  For either titration, EACI4 were prepared with 300 SFU of C1,  100 SFU of 
C4, and an amount of C2 required to yield cells bearing  1.5 C4b2a sites after spontaneous 
decay for 15 min at 30 ° C, as determined in preliminary titrations. The measurement of DAF 
activity after its incorporation into EAC14 cells was performed as follows. The EAC14 cells 
were divided into aliquots which were incubated for  15 min at 30°C with increasing concen- 
trations of DAF. After thorough washing, the DAF-sensitized cells were incubated for 5 min 
at 30 °C with the predetermined amount of C2, washed, and placed at 30°C for 15 min, and 
C4b2a  sites were  developed  by addition of C3-C9.  The  measurement of DAF  activity on 
EC142  cells (conventional assay)  was  performed  as  follows:  Another portion  of the  same 
EAC14 cells, treated for  15 min at 30°C with DGVB  ++ instead of DAF, was incubated for 5 
min at  30°C  with the same amount of C2.  The resulting EAC142  cells were  divided into 
aliquots, which were decayed for 15 min at 30 °C in the presence of increasing concentrations 
of DAF.  The  C4b2a  sites  were  developed as  above.  For  comparison,  the results of both 
titrations are  expressed as  the percent  inhibition of the C4b2a hemolytic activity and are 
plotted against the DAF concentration. (B) EAC14 cells were presensitized with ]~SI-labeled 
DAF and, after washing, incubated with C2, decayed, and C4b2a sites developed in an identical 
fashion. The percent inhibition of C4b2a hemolytic activity is shown as a function of molecules 
of DAF incorporated per cell. A  silver stain of purified DAF (28 #g/ml) after SDS-PAGE is 
shown in lane 2 of the inset in A. Buffer alone is included (lane 1) to show the background. 1562  PREVENTION  OF  COMPLEMENT  ACTIVATION  ON  CELLS  BY  DAF 
Significant inhibition of hemolysis was observed on cells incubated with DAF at 
concentrations of <1  ng/ml. 
In  a  parallel  experiment,  DAF  titration  was performed as described by Ni- 
cholson-Weller et al. (8).  EAC 14 were incubated with the same concentration of 
C2.  After  washing,  the  conventionally  prepared  EAC142  were  treated  with 
increasing concentrations of DAF and the inhibitory effect on C4b2a hemolytic 
sites measured.  As also shown in Fig.  1 A, the treatment  of EAC142 with DAF 
inhibited  C4b2a  hemolytic  activity  in  a  dose-dependent  fashion.  The  dose- 
response  curve was similar  to that  obtained after sensitization  of EAC14  with 
DAF, but, at low DAF concentrations,  less inhibition  was consistently observed 
than  with  the presensitized cells. This suggests that,  in the conventional assay, 
DAF activity may have been incorporated into the red cells before exerting its 
inhibitory effect on EAC142. 
To demonstrate that  DAF molecules were in fact associated with the red cell 
membrane,  the  sensitization  experiment  was repeated  with  125I-labeled  DAF. 
When the inhibition  of the C4b2a hemolytic activity on the sensitized cells was 
plotted against  cell-bound  ~SI-DAF counts,  a  similar  dose-response curve  was 
obtained (Fig.  1B). A small number of incorporated DAF molecules (<100) had 
a  striking  effect on the hemolytic activity. SDS-PAGE analysis and radioautog- 
raphy of an NP-40 extract of the stroma of DAF-sensitized EAC 14 cells revealed 
the presence of the radiolabeled 70,000 mol wt DAF band (not shown). 
Interestingly,  the  incorporation  of DAF into  red  cells is a  selective process. 
When an  impure  radiolabeled  DAF preparation  was used to sensitize  EAC14, 
DAF was taken  up but the  contaminants  remained  in  the  incubation  medium 
(Fig.  2).  In this experiment  we used a  DAF preparation  in which only  14% of 
the  125I counts were associated with the DAF polypeptide (Fig. 2, lane 1). When 
EA  were sensitized  with  this  preparation,  >95%  of the  counts  that  remained 
associated with  the stroma  of the red cells were identified as DAF (lane 3).  In 
addition,  as  will  be  discussed  below,  the  incorporation  of  DAF  was  totally 
inhibited  when  the  incubation  medium  contained  100  lzg/ml  of high  density 
iipoprotein (HDL) from human  serum (Fig.  2,  lane 2).  The  incorporated  DAF 
could not be removed from the stroma of the red cells by repeated washing in 
the presence of high  salt concentrations (1  M  NaC1),  but was solubilized when 
the stroma were extracted with 0.1% NP-40. 
Studies were next performed to establish some of the characteristics of DAF 
sensitization.  As shown  in  Fig.  3,  this  process is temperature  dependent.  The 
incorporation  of DAF activity into the erythrocytes was substantially greater at 
37°C  than  at  20°C  and  could not be detected at  0°C.  When  kinetics  studies 
were  repeated  using  labeled  DAF,  it  was  found  that  although  a  maximum 
functional effect was achieved within 20 min at 37 °C incubation, uptake of label 
continued to increase even after 3 h. 
We also found that the incorporation of DAF is not dependent on the presence 
of C4b on the red cells.  Indeed,  when EA were first sensitized with DAF, and 
C 1 and C4 added, the inhibitory effect on C4b2a hemolytic activity was similar 
to that observed when EAC 14 were treated with DAF under the same conditions. 
Uptake  of  DAF  also  occurred  if the  erythrocytes  had  been  pretreated  with 
trypsin  (1  mg/ml,  30  min  at  37°C)  or pronase  (100  ~g/ml,  30  min  at  37°C) MEDOF,  KINOSHITA,  AND  NUSSENZWEIG  1563 
FIGURE 2.  Selectivity  of  DAF  incorporation  into  erythrocytes.  An  incompletely  purified 
DAF preparation obtained prior to HPLC (see Materials and Methods) was labeled with 1~5I. 
When the preparation was subjected to SDS-PAGE and radioautography (lane 1), the 70,000 
mol wt DAF band was apparent but other non-DAF contaminants were also present. Some of 
these  contaminants were  identified  as  glycophorin  by  Western  blotting  using  polyclonal 
antibodies to glycophorin (not shown). The 125I-labeled  mixture was incubated for 30 min at 
30°C with EA,  the cells thoroughly washed, and the stroma dissolved with SDS.  When the 
dissolved stroma was subjected to SDS-PAGE and radioautography (lane 3),  only the DAF 
band was detected.  If,  however,  100 #g/ml of HDL  was added  to the incubation medium 
during sensitization, DAF was not taken up by EA (lane 2). 
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FIGURE 3.  Temperature dependence and kinetics of expression of DAF activity by erythro- 
cytes after DAF exposure. EACI4 (prepared with 300 SFU of CI and I00 SFU of C4) were 
incubated at 0 ° , 20 °, 30 °, or 37°C for different times with 14 ng/ml DAF in DGVB  ++. After 
thorough washing, the DAF-treated cells were incubated with C2, washed, decayed, and C4b2a 
sites  developed  as  described  in  the  legend  to  Fig.  1.  As  shown,  DAF  inhibitory activity 
increased with both time and temperature. In other experiments, using ]2SI-labeled DAF, the 
incorporation continued to increase for >3 h of incubation at 30 ° C. 1564  PREVENTION  OF  COMPLEMENT  ACTIVATION  ON  CELLS BY  DAF 
before the deposition of antibody, C 1, and C4. In this same series of experiments 
we confirmed the previous observations (8,  28) that  DAF  sensitization had  no 
discernible effect on the assembly of EAC 1 or EAC 14. 
Interestingly,  DAF  incorporation  was  blocked  by  certain  serum  proteins. 
Sensitization of red cells (or incorporation of radiolabeled DAF; see Fig. 2) was 
totally inhibited if human serum lipoproteins (HDL or LDL) were present in the 
incubation medium at concentrations of 50 t~g/ml. Bovine serum albumin (BSA) 
and  orosomucoid were also inhibitory, but only at higher concentrations, and 
ovalbumin had no effect even at a  concentration of 4  mg/ml (Fig.  4).  In sharp 
contrast with these observations, we found that LDL or HDL, even at concen- 
trations 50 times higher than those which abolished the effect of isolated DAF, 
had no effect on DAF activity that had been previously incorporated into EAC 14 
cells. The simplest interpretation of these findings is that the incorporation of 
DAF into the pseudomicelles of the  lipoproteins or its interaction with  hydro- 
phobic areas of serum albumin  or orosomucoid, prevents it from entering the 
red cell membrane and exerting its activity. However, once DAF (or one of the 
DAF domains) inserts into the nonpolar environment of the lipid bilayer of the 
erythrocyte surface  membrane,  it  cannot  interact with  those  inhibitory serum 
proteins. 
DAF Functions to Block C3 and C5 Convertase Assembly.  The ability to incor- 
porate DAF into erythrocytes permitted us to study its effect, independently of 
other regulatory factors, on the formation of complement enzymes involved in 
the early stages of complement activation. To determine the effect of DAF on 
the assembly of classical pathway C3 convertase, EAC 14 prepared with 100 SFU 
of C4 were sensitized with increasing concentrations of DAF and the cells were 
washed.  As  controls, other cell samples  were incubated  with  buffer or with  a 
103-104-fold  greater  concentration  of glycophorin A.  C2  hemolytic titrations 
were then performed with the various cell types by standard methods; that is, by 
incubating them with increasing amounts of C2, followed by treatment with C3- 
9. The amount of C2 required for lysis increased in a dose-dependent fashion as 
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FIGURE 4.  Inhibition of incorporation of DAF into erythrocytes by serum proteins. EAC 14 
(300 SFU of C1 and 100 SFU of C4) were incubated at 30"C for 30 min with 14 ng/ml DAF 
in DGVB  ++ or in the presence of increasing concentrations of serum lipoproteins (HDL or 
LDL), BSA, orosomucoid, ovalbumin, or monoclonal antibodies (57F) to CR 1. The cells were 
thoroughly washed and assayed for DAF activity as described in the legends to Figs. 1 and 3. 
HDL and LDL inhibited incorporation of DAF at low concentration. BSA and orosomucoid 
were inhibitory at higher concentrations, and ovalbumin and IgG antibodies to CR1 had no 
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a function of the DAF concentration used for sensitization  of EAC14, whereas 
glycophorin A  had no effect (Fig. 5A). 
The effect  of DAF sensitization  on formation of the alternative  pathway C3 
convertase (C3bBbP) was similarly studied. In the experiment illustrated in Fig. 
5B, EAC 143 were sensitized with three concentrations of DAF or DGVB ++. The 
DAF-  and  buffer-treated  cells  were  then  incubated  at  30°C  for  30  min  with 
increasing amounts of factor B in the presence of excess factor D and P (12 #g/ 
ml) and, after  washing,  C3bBbP sites were developed by incubation  for  1 h  at 
37°C  with C-EDTA.  Results parallel  to those observed for the C4b2a enzyme 
were  obtained;  that  is,  the  amount  of  factor  B  required  for  C3  convertase 
assembly increased  in proportion to the sensitizing dose of DAF, even when P 
was present. 
Similar  experiments  were  done  to study the  DAF  effect  on assembly  of C5 
convertase.  DAF- and buffer-treated  EAC143  cells,  prepared  with  30  SFU  of 
C3,  were  incubated  with  different  amounts  of  C2  and  the  cells  incubated 
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FIGURE 5.  Inhibition by DAF of assembly of C3 convertases of the classical (A) and alternative 
(B) pathways. In A, EACI4 (prepared as in the legend to Fig.  1) were incubated for S0 min at 
30°C  with  5,  15,  or  45  ng/ml of DAF,  or as controls with glycophorin A  (50 #g/ml) or 
DGVB  ++ containing 0.003% NP-40, which was the highest concentration of detergent present 
in the DAF-containing mixtures. The variously treated EAC 14 were then incubated for 5 min 
at 30°C with increasing concentrations of C2, as in a standard C2 titration. Without a decay 
step, the C4b2a sites were developed by addition of C3-9. DAF sensitization inhibited C4b2a 
formation in a  dose-dependent fashion, while glycophorin A  or NP-40 bad no effect.  In B, 
EACI43 (prepared as described in Materials and Methods) were similarly incubated with 5, 
15, or 45 ng/ml of DAF or with buffer as control. After thorough washing, the treated cells 
in DGVB  ++ were incubated at 30°C for 30 min with increasing amounts of factor B in the 
presence  of excess  factor  D  and  12  pg/ml  P.  The  cells were  washed  and  C3bBbP  sites 
developed by addition of C3-9.  DAF sensitization inhibited the assembly of the alternative 
pathway enzyme in a dose-dependent fashion. 1566  PREVENTION  OF  COMPLEMENT  ACTIVATION  ON  CELLS  BY  DAF 
sequentially with 300 SFU of C5 and C6-9. As shown in Fig. 6, DAF sensitization 
markedly reduced  the  efficiency of assembly of C5  convertase activity on  the 
EAC t 43 cells. 
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FmURE  6.  Inhibitory effect of DAF on C5 convertase assembly. EAC143 were sensitized at 
30°C for 30 min with DAF (45 ng/ml) in DGVB  ÷+ or with buffer as in the legend to Fig. 5. 
The DAF-treated and control cells were then incubated with increasing concentrations of C2 
and, after washing, the resulting C4b2a3b sites on the two cell types developed by incubation 
for 5  min at  30°C with C5 and 60  min at  37°C with C6-C9,  Generation of the C4b2a3b 
enzyme was markedly reduced on the DAF-treated cells. 
1.0 
~  0.8 
~  0.6 
0.4 
0.2 
2.0 
1.6 
O0 
N  1.2 
~  0.8 
0.4 
® 
~--EAC,4 
cEAC~ (~e) 
I  I  I  I  I 
32  16  8  4  2 
Reciprocal  Dilution  of  C2 
#  EAC43 (DAF.~) 
~T  I  I 
10  30  100 
Factor  B  Concentration (/~j/ml) 
FIGURE 7.  Blockage by membrane-associated  DAF of C4b (A) and C3b (B) hemolytic activity 
on EAC14.m and EAC143,m cells. In A, EACl4tim were incubated at 30°C for 30 min with 14 
ng/m] DAF or buffer. The cells were incubated at 30°C for 5 min with C2 over an extended 
range of concentrations and C4b2a  sites developed by addition of C3-9.  In B,  EACI43ti= 
sensitized with DAF or treated with buffer in the same way were incubated at 30°C for 30 
min with factor B (in DGVB  ++) over an extended range of concentrations, in the presence of 
excess D and 12 #g/mi P, and CBbBbP sites were developed by addition of C3-9. The DAF- 
mediated inhibition of classical  or  alternative pathway  C3  convertase formation  was  not 
overcome by augmenting the C2 or factor B concentrations. MEDOF,  K1NOSHITA,  AND  NUSSENZWEIG  1567 
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FIGURE 8.  Effect of metals on assembly and decay of alternative pathway C3 convertase on 
DAF-containing erythrocytes. EAC1431im were incubated at 30°C for 30 min with DAF (14 
ng/ml) or with DGVB  +÷ as a  control. The washed DAF-treated and control cells were then 
incubated at 30°C for 30 rain with 100 #g/ml factor B, excess factor D, and  12 #g/ml P in 
buffer containing 0.5 mM Mg  ÷÷ or buffer containing 0.1  mM Ni  ÷÷. The different cell types 
were then placed at 30°C, and C3bBbP sites developed after progressively longer incubation 
times as  described in Materials and Methods.  In the presence of Ni  ÷÷,  the initial C3bBbP 
hemolytic activity on  the  DAF-treated  cells approached  that on  the control  cells,  but  the 
enzyme subsequently decayed at a faster rate. 
The above studies were performed using EAC14 or EAC143 bearing excess 
C4b or C3b. When they were repeated using cell intermediates bearing limited 
C4b or CSb, the effects of DAF were even more striking.  After incubation  of 
the DAF-treated EAC141im with up to S,000 SFU of C2 or °xYC2 (Fig.  7A), the 
number of hemolytic sites per cell (Z) was only 0.2, while after incubation of the 
buffer-treated  EACl4tim with  30 SFU of C2, Z was 0.9.  Similarly,  when  DAF- 
treated EAC4Slim were incubated with factors B (100 pg/ml), D, and P, the CSb 
hemolytic activity was reduced >80% relative to the control cells (Fig. 7B). 
Because of the reported enhancing  activity of Ni  ÷÷ or high  Mg  ÷+ concentra- 
tions on  the assembly of alternative  pathway CS  convertase (29,  30),  next  we 
studied the effects of these ions on DAF activity. We found that raising the Mg  ++ 
concentration  in the incubation  medium from 0.5 to 5 mM or substituting  0.1 
mM  Ni  +÷ for  Mg  +÷ partially  overcame  the  inhibitory  activity of DAF.  In  the 
series of experiments  shown in  Fig.  8,  DAF-treated  EAC4S,m or control  cells 
were treated with factor B (100 #g/ml), D, and P in the presence of physiological 
Mg  ++  concentrations  (0.5  mM)  or  in  the  presence  of Ni  ++  (0.1  mM).  After 
washing,  the  cells were placed at  S0°C and  the kinetics of dissociation  of the 
C3bBbP enzyme on the different cell types was compared. As expected, when a 
physiological  Mg  ÷÷  concentration  was  used  at  the  start  of the  experiment, 
substantially  lower C3b hemolytic activity was detectable on  the  DAF-treated 
ceils relative to the control cells, but the decay rates of the enzymes on both cells 
were comparable. When Ni  ++ was substituted for Mg  ÷+, the effect of DAF was 
overcome; that  is,  the  initial  CSb hemolytic activity on  the  DAF-treated  cells 
increased to that on the nontreated cells. However, the rate of decay of the Ni +÷- 
stabilized enzyme generated on the DAF cells was substantially faster than that 1568  PREVENTION  OF  COMPLEMENT  ACTIVATION  ON  CELLS  BY  DAF 
of the  Mg  ++ (or  Ni++)-dependent  enzyme generated  on the control  cells.  It is 
known  that  raising  the  Mg  ++  concentration  or  substituting  Ni  ÷+  for  Mg  ÷+ 
increases the binding affinity of factor B for C3b (29,  30). The present results 
indicate that  this maneuver  has facilitated the assembly of alternative  pathway 
convertase experimentally in vitro on DAF-containing E hu and explain previous 
observations by others (9,  14). 
Mechanism of Action  of DAF.  In  view of the  above findings  that  DAF  can 
render C4b and C3b sites functionally inert, it was important to ascertain whether 
DAF alters  the  C4b/C3b structure  and  how it blocks convertase assembly.  In 
one series of experiments,  buffer-treated and DAF-treated EAC14 were either 
incubated  with  anti-DAF  polyclonal  IgG  antibodies  or  with  preimmunization 
IgG, and  the cells analyzed for C4b hemolytic activity. As seen in  Fig.  9, pre- 
treatment  with  rabbit anti-DAF  antibodies  completely restored  the  C4b func- 
tional activity on the DAF-treated cells, while pretreatment  with normal rabbit 
IgG had  no effect. The  DAF  effect was fully reversible even when  the  DAF- 
treated  EAC14  were  preincubated  at  37°C  for  2  h  before  treatment  with 
antibody. Additional studies were done in which the DAF-treated EAC 14 were 
incubated  with  C2  and  the  cells allowed to decay before the addition  of anti- 
DAF  antibodies.  Complete  restoration  of the  C4b  functional  sites  was again 
observed. Anti-DAF antibodies also fully restored the C3b hemolytic activity of 
EAC431im cells sensitized with DAF. 
To study directly the effect of DAF on C3b and C4b structure, we prepared 
EAC431im cells with  ~25I-C3. After sensitization  of the labeled intermediate  with 
DAF (10 ng/ml)  and titrations  to confirm  that  the C3b hemolytic activity was 
diminished  by  ~80%,  the  cells were  lysed and  the  stroma  subjected to  SDS- 
PAGE and radioautography.  No changes in the apparent  molecular weights of 
the a  and/3 chains of C3b were observed. In further studies,  the  DAF-treated 
EAC431im prepared with ~5I-C3 were mixed with excess factors B, D, and P and, 
after 30 min incubation at 30 °C, subjected to SDS-PAGE and radioautography. 
As before, the C3b gel patterns remained unchanged (not shown). 
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FIGURE 9.  Reversibility of the DAF effect on EAC 14 by anti-DAF antibodies. EAC14 (300 
SFU C 1 and 1  O0 SFU C4) were incubated with 14 ng/ml of DAF or buffer as a control. After 
thorough washing, the cells were then incubated for 15 min at 30°C and 15 min at 0°C with 
increasing concentrations of IgG from a rabbit anti-DAF antiserum or with preimmunization 
IgG. After another thorough washing, C4b sites on the cells were developed by incubation at 
30°C for 5  min with 300 SFU of C2 and C4b2a sites developed by addition of C3-9. The 
percent reversal of DAF-mediated inhibition of C4b hemolytic activity is shown as a function 
of  IgG  concentration.  The  anti-DAF antibodies  restored  the  hemolytic  activity  of  DAF- 
sensitized cells, while the preimmunization IgG had no effect. MEDOF,  KINOSHITA,  AND  NUSSENZWEIG  1569 
We also performed experiments to verify whether, after its incorporation, the 
DAF inhibitory effect could be enhanced by further incubation of the sensitized 
ceils at 37°C.  EAC14 cells prepared  with  300 SFU of C4  were sensitized with 
suboptimal concentrations of DAF (1 ng/ml) for 30 min at 30°C. The cells were 
washed and reincubated at 37 ° C. At various times thereafter, up to 2 h, samples 
were removed and  C2  titrations  performed.  The  DAF  inhibitory  activity was 
identical in all samples, suggesting that once incorporated into the cell membrane, 
DAF inhibits C4b function stoichiometrically, not enzymatically. 
DAF could-act to prevent C3 convertase formation either by blocking uptake 
of C2 and factor B or preventing  conversion of C4b-bound C2  or C3b-bound 
factor B zymogens to enzymatically active C2a or Bb fragments.  This question 
was examined using the alternative pathway enzyme. Portions of EC 143Jim were 
sensitized  with  DAF,  or,  alternatively,  incubated  with buffer as control,  After 
washing,  the two cell  types were assayed in parallel  studies for C3b hemolytic 
activity and for uptake of ~25I-labeled factor B. Diminished C3b hemolytic activity 
on the DAF cells relative to the buffer control cells was associated with reduced 
uptake of 125I-factor  B (not shown). In a further experiment, uptake of 12~I factor 
B on DAF-treated EAC431im cells was induced by adding 0.1  mM Ni  ÷+ instead 
of Mg  ÷+ and, after decay at 30°C for 30 min, the supernatant and stroma of the 
cells were subjected to SDS-PAGE. No unusual factor B fragments were detected 
either still  associated with  the  DAF cells or released into the supernatant  (not 
shown). 
DAF Can Only Function Intrinsically Within the Cell Membrane.  Studies were 
next undertaken to determine whether membrane-associated DAF only functions 
intrinsically  or also can act extrinsically,  that  is inhibit  C3  convertase on other 
cells. In the first series of experiments we evaluated the influence of cell dilution 
on  the activity of membrane-associated  DAF.  We reasoned  that  if DAF acted 
extrinsically, its effect should be highly dependent on the cell concentration.  EA 
were sensitized with DAF or incubated with DGVB  ++ as control and then reacted 
stepwise with C 1, C4, and limiting C2. After washing, aliquots of the cells were 
suspended into progressively larger volumes of ice-cold DGVB  ÷+, to concentra- 
tions of 106-108/ml.  The  cell suspensions  were placed at  30°C for  15  min to 
decay and the residual C4b2a hemolytic activity was measured.  We found that 
although  the hemolytic activity of DAF-sensitized EAC142 was lower than that 
of EAC142 (Z =  0.090 and 0.330, respectively), for each cell type the degree of 
hemolysis was constant and independent of cell concentration. 
Next,  we  studied  directly  the  effect of DAF-containing  cells on  the  C4b2a 
enzyme assembled on non-DAF-containing cells. In one set of experiments (Fig. 
10A), aliquots of EAC142 were mixed with equal numbers of EA, DAF-treated 
EA, or buffer. The mixtures were then placed at 30°C and the kinetics of decay 
of C4b2a measured.  The rate of decay was identical  in all samples.  In another 
set  of experiments,  we  used  intact  E  hu  as  a  source  of  DAF.  EAC142  were 
incubated with increasing numbers of intact E  hu for 30 min at 30°C. As shown 
in Fig.  10B, E h° inhibited C4b2a enzymatic activity in a dose-dependent fashion, 
but this effect was mediated by the complement receptor CR1  also present on 
E hu, and not by DAF.  Indeed, polyclonal anti-DAF antibodies had no effect on 
the Eh"-mediated inhibition of C4b2a, while anti-CR1  completely reversed it. 1570  PREVENTION  OF  COMPLEMENT  ACTIVATION  ON  CELLS  BY  DAF 
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FIGURE 10.  Inability of membrane-incorporated DAF to inhibit C3 convertase extrinsically 
on substrates.  The effect of DAF-containing cells on the decay rate of C4b2a assembled on 
non-DAF-containing cells is shown in A. EACI42 (5 ×  107/ml) prepared as described in the 
legend to Fig.  1, were mixed with an equal number of DAF-sensitized EA, which had been 
prepared  with  14  ng/ml  DAF and  thoroughly washed.  HDL (50 #g/ml) was  added  to the 
buffer and the mixtures placed at 30°C. The decay of C4b2a on EAC142 was then measured 
as a function of time as described in Materials and Methods. The decay of C4b2a on EAC 142 
prepared in an identical fashion and mixed with nontreated EA was also measured in parallel 
as a control. As shown, the presence of DAF in the DAF-treated EA inhibited the formation 
of C4b2a on these cells. However, the addition of DAF-treated EA to the incubation mixture 
had  no  effect on  the  decay  rate  of C4b2a  on  non-DAF-treated  cells.  (B)  The  ability of 
monoclonal anti-CR 1 antibodies to reverse the extrinsic C3 convertase inhibition mediated by 
intact E  h". EAC1421~m (5 X 107/ml) prepared with 300 SFU of C1,  100 SFU of C4, and ~1.5 
SFU of C2 were incubated for 30 min at 30°C with increasing numbers of intact E  h" in the 
absence or presence of pooled monoclonal anti-CR1  antibodies (57F,  44D,  and  3 I D).  The 
cells were washed and C4b2a hemolytic activity developed by addition of C3-9. Control tubes 
containing E  ~" alone were included, and the optical density of the hemoglobin released was 
subtracted  from  the  optical  density  in  the  experimental  tubes.  The  anti-CR1  antibodies 
completely blocked the extrinsic inhibitory effect of the E  h" on C4b2a assembled on the sheep 
cells.  In several other experiments, we found that polyclonal mouse or rabbit anti-DAF had 
no effect at concentrations that reversed the DAF effect on DAF-sensitized sheep cells. 
To  establish  whether  the  intrinsic  inhibitory  effect  of  DAF  on  complement 
activation can in fact diminish  lysis of cells by complement,  we performed  studies 
with rabbit erythrocytes,  known  to be strong activators of the alternative  pathway 
in human  serum  and  not to be subject  to regulation  by factors  I  and  H  (31,  32). 
Rabbit  erythrocytes  were  sensitized  with  increasing  concentrations  of  human 
DAF  or  incubated  with  buffer  as  control.  After  thorough  washing,  aliquots  of MEDOF,  KINOSHITA,  AND  NUSSENZWEIG  1571 
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FIGURE  1 I.  Effects of membrane incorporation of DAF on the sensitivity of rabbit erythro- 
cytes to hemolysis by human complement. The rabbit cells were pretreated with different 
amounts of DAF, as in Fig. 5, and washed. Aliquots of ] 00/~1 of the DAF-treated or nontreated 
control cells (]  x  108/ml) in GVB containing !mM  EGTA and !  mM MgCI2 were incubated 
with ! 00 #1 of various dilutions of human serum. After ] 5 rain at 30 ° C, ! .8 ml of GVB-EDTA 
were added, the cells pelleted, and the percent lysis determined. 
the  DAF-treated  and  control  cells  were  incubated  at  30°C  for  10  min  with 
decreasing dilutions of Mg++-EGTA human serum.  The cells were then diluted 
with  ice-cold  buffer  and  centrifuged,  and  lysis was  measured  (Fig.  11).  The 
amount  of  human  serum  required  for  lysis  increased  as  a  function  of the 
concentration  of DAF used to sensitize the cells.  In control studies,  the rabbit 
erythrocytes were incubated with  100 #g/ml of purified glycophorin A  instead 
of DAF, and no effect was observed. Moreover, similar to the results in Fig. 2, 
only  the  70,000  mol  wt  DAF  band  could  be  detected  in  the  washed  rabbit 
erythrocyte stroma when these cells were sensitized with partially purified DAF. 
As an additional control, we found that the DAF-mediated inhibition of lysis was 
reversed when  the  DAF-containing  rabbit cells were exposed to anti-DAF  but 
not to anti-glycophorin antibodies. 
Discussion 
In the present study, we purified DAF to homogeneity from human red cell 
stroma and found that it exhibits the unique property of being able to reassociate 
with red cells and express its biological activity. Association with the cells does 
not depend upon the prior presence of deposited complement components, since 
the uptake of DAF proceeds efficiently on EA or untreated E. After membrane 
binding,  the  incorporated  DAF has some properties  of an  integral  membrane 
protein.  It  cannot  be removed  by repeated  washing  of the  cells,  even  in  the 
presence of high salt concentrations, but can be extracted with buffers containing 
detergents.  The  conditions  under  which  membrane  incorporation  of DAF oc- 
curs,  and  the  efficiency  with  which  the  reincorporated  molecule  exerts  its 1572  PREVENTION  OF  COMPLEMENT  ACTIVATION  ON  CELLS  BY  DAF 
biological  effect  (Fig.  1),  suggest  that  the  accelerated  decay  dissociation  of 
EAC142,  previously observed  upon  exposure  to  DAF  (8),  involves  its  prior 
membrane incorporation into the cellular intermediate. 
The precise mechanism of DAF incorporation into the cell membrane is not 
clear. The temperature dependency of the uptake (Fig.  3) is compatible with a 
process requiring membrane mobility.  One possibility  is that  DAF binds to a 
specific  membrane acceptor  molecule.  The  incorporation  was  not  abolished, 
however, by pretreatment of the cells with trypsin or pronase, indicating that, if 
specific acceptor sites exist, they are either not accessible or not susceptible to 
proteolysis by these enzymes. An alternative possibility is that DAF is inserted 
into the lipid bilayer nonspecifically via a hydrophobic domain. The observation 
that DAF binds tightly to phenyl-Sepharose (8) and can be removed only with 
high concentrations of detergent supports the existence of such a domain in the 
molecule. The strong inhibitory effect of LDL and HDL on red cell incorporation 
(Fig.  4)  may be  due to  the tendency of DAF  to  alternatively insert  into  the 
pseudomicelles of these lipoproteins. Hydrophobicity of a DAF domain may also 
explain the finding that, in purified form, the protein appears to be a multimer. 
Indeed, isolated DAF has an apparent molecular weight of _>150,000 by molec- 
ular sieve chromatography performed in the presence of different amounts of 
detergents,  below or above the critical  micellar concentration (manuscript in 
preparation). 
The finding that incorporation of DAF into membranes is a  highly selective 
process may have relevance to the interesting prior reports of Okada et al. (33, 
34). They observed that erythrocytes  were not lysed by heterologous complement 
if they  were  pretreated  with  a  glycophorin  preparation  homologous  to  the 
complement source, and suggested that the bound glycophorin prevented com- 
plement activation. Our studies with sheep cells, using a partially purified DAF 
preparation  containing glycophorin, showed that only DAF was incorporated 
(Fig. 2).  Moreover, we performed studies similar to theirs using rabbit erythro- 
cytes, except that we treated the cells with either purified DAF or glycophorin. 
Only DAF was incorporated, and it enhanced the resistance of the red cells to 
lysis by human complement (Fig.  11).  It therefore seems possible that Okada's 
glycophorin preparation contained DAF. 
The ability to incorporate DAF into cell membranes is of great interest for at 
least two reasons. In the first place, it permits the study of DAF function on the 
early steps of complement activation in selected microenvironments, as well as 
its  potential  effect at  other  stages  of the  complement cascade,  for example, 
formation of terminal pathway complement complexes. In addition, it raises the 
intriguing possibility of correcting in vitro the defect in the membranes of cells 
from patients with PNH, which would demonstrate directly that DAF deficiency 
is the cause of the clinical abnormality. 
Once  integrated  with  the  cell  membrane,  DAF  acts  primarily  to  prevent 
convertase assembly on the cell surface. Formation of C3 and C5 convertases of 
both the classical and alternative pathways is blocked. When added to EA, DAF 
does not interfere with the deposition of C 1 or C4. The inhibition of the classical 
pathway enzymes occurs at the level of C2 and cannot be bypassed by augmenting 
the  C2  concentration.  The  presence of as  few as  70  DAF  molecules in  the MEDOF,  KINOSHITA, AND  NUSSENZWEIG  1573 
membrane markedly inhibited C4b2a assembly (Fig.  1 B). This striking effect of 
DAF  in  preventing  C2  activation  is  the  most  likely  explanation  of previous 
observations  by  Brown  et  al.  (28)  that,  after  sensitization  with  antibody,  E hu 
consume and take up C 1 and C4 as efficiently as sheep E, but do not consume 
C2. 
By acting primarily to prevent formation of convertases, the membrane factor 
can function to block the hemolytic activity of C4b or C3b fragments inadvert- 
ently deposited on host membranes,  while simultaneously preventing  turnover 
of C2 and/or  factor B. Although  the membrane  factor can also accelerate the 
decay of preformed convertase complexes (8, 9, 14), and therefore can addition- 
ally act to immediately dissociate any complexes that escape the block of conver- 
tase  formation,  it  could be argued  that  the present  nomenclature,  i.e.,  decay- 
accelerating factor, does not accurately reflect its main function. 
Several lines of evidence indicate that  DAF prevents the binding  of C2 and 
factor B zymogens to C4b and C3b, respectively. Pangburn et al. (14) previously 
found that  DAF accelerates  the  dissociation  of C3bBb assembled on zymosan 
particles.  We demonstrated here that when EAC14 cells were sensitized with a 
limiting  amount  of DAF,  the  extent  of inhibition  of the  convertases did  not 
increase regardless of the time of incubation, indicating that the DAF effect was 
stoichiometric,  not enzymatic.  Gel patterns  of C3b after  DAF sensitization  of 
EAC43  were  unchanged.  More  important,  reduced  C4b  and  C3b  hemolytic 
activities on DAF-treated EACI4 and EAC43, respectively, were fully restored 
after incubation of the cells with anti-DAF antibodies, indicating that DAF does 
not alter  C4b or  C3b structure  in  some unusual  way not apparent  in  the  gel 
patterns.  Finally, decreased hemolytic activity on EAC43 cells exposed to DAF 
correlated with decreased uptake of 125I-labeled  factor B. The simplest interpre- 
tation  for all  these  findings  is  that  DAF associates  within  the  cell  membrane 
directly with C4b and C3b, thereby preventing uptake of C2 and factor B. 
When the regulatory factor is membrane  incorporated, and presumably is in 
its native state, it inhibits convertase formation on the same membrane, but does 
not influence the formation or stability of convertases assembled on other nearby 
cells or  substrates.  Indeed,  the  rate  of decay of C4b2a  hemolytic activity  on 
DAF-treated cellular intermediates  was not influenced  by dilution  of the cells, 
indicating that DAF in the membrane of neighboring cells did not contribute to 
the decay. The addition of DAF-sensitized  EA to nontreated  EAC 142 did not 
alter the decay rate of the C4b2a enzyme on the neighboring cells. The inhibitory 
effect of intact  E hu on EAC 142 was not diminished  by antibodies to DAF but 
instead was totally abolished with monoclonal anti-CR 1 antibodies. Finally, serum 
proteins inhibited  the function of purified  DAF before it was taken  up by the 
red cells, but did not affect the function of membrane-incorporated  DAF. The 
ability of DAF to function only within the membrane may relate to the manner 
in  which  it  is oriented  spatially and/or  the  way in  which  it  interacts  with  the 
covalently bound C4b or C3b. 
In  Fig.  12 we represent schematically our current  hypothesis explaining  the 
results described in this and previous papers. We postulate that DAF contains a 
hydrophobic domain  in close proximity to its active site.  In the purified  state, 
DAF is aggregated and inactive, or poorly active, because its binding site is not 1574  PREVENTION  OF  COMPLEMENT  ACTIVATION  ON  CELLS  BY  DAF 
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FIGURE  12.  Schematic representation  of the proposed mechanism of action  of DAF  and 
CR1  on C3 and C5 convertases assembled on host cells or on substrates. Both DAF and CR1 
can prevent the assembly of the enzymes by competing with factor B and C2 for sites on C3b 
and C4b. However, DAF can only act intrinsically, while CRI  can reach C3b or C4b clusters 
on neighboring cells or substrates such as immune complexes. CR 1 is represented in a clustered 
form (41 ). 
fully available to the exterior, or because of allosteric changes in the molecule. 
When  DAF  is  incorporated  into  the  cell  membrane,  through  its hydrophobic 
domain,  its original  configuration  is reestablished and it can now interact  with 
C3b or C4b, mostly associated with glycophorin molecules (35,  36). DAF must 
be fully mobile  in  the  plane  of the  membrane  in  order  to  come rapidly  into 
contact with the scarce C4b or C3b ligand deposited elsewhere on the surface of 
the cell. Also, according to this concept, the active site on CR1, which is a much 
larger  molecule,  can  reach  C3b and  C4b on neighboring  cells (or  in  immune 
complexes) (2, 3, 37) but the active site of DAF is unavailable to the exterior. 
The  molecular mechanisms  responsible for the protection of host cells from 
the deleterious effects of activation of autologous complement on their surface 
have  been  the  subject of extensive  investigations  and  speculations.  Although 
sialic acid has been shown to play an important  role in controlling activation of 
the alternative pathway (32,  38,  39), E h" still  resist lysis by human  complement 
after desialation. In view of this finding and of the observation that C3 convertase 
can be inhibited  by CR1, it has been proposed (4) that  the CR1  molecule also MEDOF,  KINOSHITA, AND  NUSSENZWEIG  1575 
plays a role in the intrinsic control of complement activation in cell membranes. 
The results of the present  paper suggest that  this  intrinsic  control  is the  main 
function  of DAF  rather  than  of CR1.  This  notion  is  in  agreement  with  the 
observations of Okada et al.  (40)  who found that  nucleated  cells lacking  CR1 
resist  lysis by complement  even after  their  desialation.  Also, the  complement- 
sensitive red cells of patients with PHN are DAF deficient but can have normal 
levels of CR1 (14). 
In  short,  it  appears  that  the  70,000  mol  wt  DAF  molecule  may  not  only 
safeguard autologous cells against  the results of spontaneous activation via the 
alternative  pathway,  but  could  also  protect  them  from  the  classical  pathway 
cascade if they were to be recognized by autoantibodies. The strict restriction of 
DAF functional activity to the cell membrane would prevent progression of the 
cascade on host cells but not impair the initiation and amplification of the cascade 
on foreign substrates. 
Summary 
Decay-accelerating factor (DAF), extracted from the stroma of human  eryth- 
rocytes, was purified  to homogeneity and  incorporated  into the  membrane  of 
sheep red cell complement intermediates,  where its functional properties were 
analyzed.  Incorporation  of  DAF  into  the  cell  membranes  was  temperature 
dependent, took place on pronase- or trypsin-treated erythrocytes, and did not 
depend on prior deposition of antibody, C 1 or C4. Serum lipoproteins (high and 
low density) effectively inhibited  DAF incorporation,  but had no effect on the 
activity of DAF after its association with the cell membrane.  The incorporated 
DAF could not be removed from the red cell surface by repeated washings in 
the presence of high salt concentration but was solubilized when the stroma were 
extracted with 0.1% Nonidet P-40. 
The presence of DAF in the membrane of EA did not affect the deposition of 
C 1 and C4, but as few as  102 DAF molecules per cell profoundly inhibited  the 
assembly of C3 and C5 convertases of both the classical and alternative pathways. 
The DAF inhibitory effect on EAC14 or EAC43 was not overcome by supplying 
an excess of C2 or factor B, but the alternative pathway C3 convertase could be 
assembled in the presence of Ni  ÷+, or nonphysiological concentrations of Mg  ++, 
which enhances  the  binding  affinity of factor  B  for C3b.  The  DAF effect on 
EAC14 or EAC143 was entirely reversed by treating the cells with specific anti- 
DAF antibodies,  showing that  DAF did not alter the structure of C4b or C3b. 
Taken together, the experimental evidence suggests that DAF interacts directly 
with membrane-bound  C3b or C4b and prevents subsequent uptake of C2 and 
factor B. 
DAF can function only within the cell membrane.  Indeed, the decay dissocia- 
tion  of the  C4b2a  enzyme  on  DAF-containing  sheep  intermediates  was  not 
changed by varying the cell concentration.  DAF-treated EA had no influence on 
the decay of nontreated  EAC142  present  in  the same mixture.  Moreover,  the 
inhibitory activity of intact  human  erythrocytes on C4b2a was not blocked by 
antibodies to  DAF, but was abolished by antibodies  to the  C3b/C4b receptor 
(CR1).  When  incorporated  into  the  membrane  of rabbit erythrocytes,  human 
DAF inhibited their lysis by human complement. 1576  PREVENTION  OF  COMPLEMENT  ACTIVATION  ON  CELLS BY  DAF 
In conclusion, on the basis of these and previous results, it appears that DAF 
plays a  central role in preventing the amplification of the complement cascade 
on host cell surfaces.  While  DAF  can  act only intrinsically to protect the host 
cells,  CR1  inhibits  the  assembly  of the  convertases extrinsically on  substrates, 
such as immune complexes, which may come in contact with host cells. 
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and Joanne Joseph, Randi Klein, and Roger Rose for manuscript preparation. 
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